Showing results (421-430 of 456) with videos related to

Sort By:
Pageof 46
Advances in Experimental Medicine and Biology|February 23, 1999
Targeted reduction of oxytocin expression provides insights into its physiological rolesW S Young, E Shepard, A C DeVries, et al.
Cancer Research|September 24, 1999
Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa)J Zhao, J Richter, U Wagner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian CancerBois A du, W Meier, H J Lück, et al.
British Journal of Cancer|July 28, 2012
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsU Wagner, C Marth, R Largillier, et al.
Die Rehabilitation|January 12, 2008
[Lymphedema in patients with breast cancer--a consensus regarding diagnostics and therapy in patients with postoperative lymphedema after primary breast cancer]U Seifart, U-S Albert, M-E Heim, et al.
Zentralblatt Fur Gynakologie|June 4, 1999
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]U Wagner, S Köhler, G Prietl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2001
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001U Wagner, S Köhler, S Reinartz, et al.
Gynecologic Oncology|January 22, 2005
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)A du Bois, A Belau, U Wagner, et al.
Gynecologic Oncology|July 8, 2011
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study GroupK Baumann, J Pfisterer, P Wimberger, et al.
Physical Review Letters|March 14, 2003
Proton acceleration from high-intensity laser interactions with thin foil targetsM Zepf, E L Clark, F N Beg, et al.
Pageof 46